TEV-48574

Phase 2Small molecule

Teva

TEV-48574 is one of 57 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

AsthmaActive, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Cinqair

Teva

Preclinical

13 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Formoterol Fumarate

AstraZeneca

Preclinical

8 7

Symbicort

AstraZeneca

Preclinical

6 8

TEV-48574

Teva

Phase 2

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Active, not recruiting

Ulcerative Colitis

NCT05668013

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Active, not recruiting· Teva logo

Teva·Phase 2·NCT05668013·247 enrolled

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Completed· Teva logo

Teva·Phase 2·NCT05499130·290 enrolled

Asthma1 trial

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Terminated· Teva logo

Teva·Phase 2·NCT04545385·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TEV-48574. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TEV-48574 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TEV-48574. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Teva

TEV-48574

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Ulcerative Colitis2 trials

Asthma1 trial

References

Drug Info

Quick Facts

Related News